Listing of Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

1.(currently amended) A compound of the Formula (I):



(I)

wherein:

the configuration at the steriogenic center (*) may be R, S, or RS (the racemate);

R_1 is selected from $C_1 - C_6$ alkoxy**[[,]]**; and

R_2 is selected from H, or $C_1 - C_6$ alkyl; or, pharmaceutically acceptable salt**[[s]]** or hydrate**[[s]]** thereof.

2.(original) A compound of Claim 1 which is 2,2-dimethyl-propionic acid 4-[2-dimethylamino-1-(hydroxy-cyclohexyl)-ethyl]-phenoxymethylester, or a pharmaceutically acceptable salt or hydrate thereof.

3.(currently amended) A pharmaceutical composition comprising a pharmaceutically effective amount of a compound of Formula I:



(I)

wherein:

the configuration at the steriogenic center (*) may be R, S, or RS (the racemate);

R_1 is selected from $C_1 - C_6$ alkoxy**[[,]]**; and

R_2 is selected from H, or $C_1 - C_6$ alkyl; or, pharmaceutically acceptable salt**[[s]]** or hydrate**[[s]]** thereof; and a pharmaceutically acceptable carrier or excipient.

4.(currently amended) A method of treating disorders of the central nervous system in a mammal, said disorders being selected from depression, anxiety, generalized anxiety disorder, panic disorder, post-traumatic stress disorder, late luteal phase dysphoric disorder, attention deficit disorder with and without hyperactivity, obsessive compulsive disorder, social phobias, bulimia nervosa, Gilles de la Tourette Syndrome, Shy Drager Syndrome, vasomotor flushing, drug addiction, alcohol addiction, cocaine addiction, tobacco use, sexual dysfunction, premature ejaculation, borderline personality disorder, chronic fatigue syndrome, fibromyalgia, urinary incontinence, chronic obstructive pulmonary disorder, migraine, Raynaud's Syndrome, postherpetic neuralgia, pain, chronic back pain, obesity, senile dementia, Parkinson's Disease, epilepsy, Alzheimer's disease, amnesia, amensic syndrome, autism, and schizophrenia, the method comprising providing to a mammal in need thereof a pharmaceutically effective amount of a compound of Formula I:



(I)

wherein:

the configuration at the steriogenic center (*) may be R, S, or RS (the racemate);

R_1 is selected from $C_1 - C_6$ alkoxy**[[,]]**; and

R_2 is selected from H, or $C_1 - C_6$ alkyl; or, pharmaceutically acceptable salt**[[s]]** or hydrate**[[s]]** thereof.

5.(original) The method of Claim 4 wherein the central nervous system disorder is depression.

6.(original) The method of Claim 4 wherein the central nervous system disorder is generalized anxiety disorder.

7.(original) The method of Claim 4 wherein the central nervous system disorder is panic disorder.

8.(original) The method of Claim 4 wherein the central nervous system disorder is post traumatic stress disorder.

9.(original) The method of Claim 4 wherein the central nervous system disorder is attention deficit disorder, with and without hyperactivity.

10.(currently amended) The method of Claim 4 wherein the central nervous disorder is a neurodegenerative disorder selected from senile dementia, Parkinson's Disease, epilepsy, Alzheimer's disease, amnesic syndrome, and Shy Drager Syndrome.

11.(canceled)

12.(original) The method of Claim 4 wherein the central nervous system disorder is anxiety.

13.(original) The method of Claim 4 wherein the central nervous system disorder is schizophrenia or borderline personality disorder.

14.(original) The method of Claim 4 wherein the central nervous system disorder is cocaine and alcohol addiction.

15.(original) The method of Claim 4 wherein the central nervous system disorder is late luteal phase dsyphoric disorder (also known as premenstrual syndrome).

16.(original) The method of Claim 4 wherein the central nervous system disorder is autism.

17.(original) The method of Claim 4 wherein the central nervous system disorder is bulimia nervosa, Gilles de la Tourette Syndrome, vasomotor flushing, and chronic fatigue syndrome.

18.(currently amended) **[[**The**]]** A method of ~~Claim 4 wherein the central nervous system disorder is~~ treating urinary incontinence or chronic obstructive pulmonary disorder, comprising providing to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 1, or pharmaceutically acceptable salt or hydrate thereof.

19.(original) The method of Claim 4 wherein the central nervous system disorder is pain.

20.(original) The method of Claim 4 wherein the central nervous disorder is postherpetic neuralgia.

21.(original) The method of Claim 4 wherein the central nervous system disorder is sexual dysfunction.

22.(currently amended) A method of enhancing cognition in a mammal, the method comprising providing to a mammal in need thereof a pharmaceutically effective amount of a compound of Formula I:



(I)

wherein:

the configuration at the steriogenic center (*) may be R, S, or RS;

R_1 is selected from $C_1 - C_6$ alkyl, $C_1 - C_6$ alkoxy, C_3-C_6 cycloalkyl, or the moiety:



(a);

R_2 is selected from H, or C_1– C_6 alkyl; or,

R_1 and R_2 may be concatenated such that  , form a moiety having formula (b):  (b);

R[[3]]$_3$ is selected from H or $C_1 - C_6$ alkyl; and

~~R4 and R5~~ R_4 and R_5 are independently selected from H, $C_1 - C_6$ alkyl, C_3-C_6 cycloalkyl, $C_1 - C_6$ alkoxy, $C_1 - C_6$ thioalkoxy, -CN, -OH, $-CF_3$, $-OCF_3$, halogen, $-NH_2$, $-NO_2$, or mono or dialkylamino wherein each alkyl group has 1 to 6 carbon atoms, or a pharmaceutically acceptable salt or hydrate thereof.